The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases.
34 participants with biopsy-proven prostate cancer and cancer seen on a Pylarify PET scan will be enrolled in this study.
The investigational 61Cu-NU101 PET/CT will be perfromed. If there is a difference between the standard Pylarify exam and the investigational 61Cu-NU101 exam, a biopsy of one lesion that is different between the two exams may be performed.
Biopsy proven prostate adenocarcinoma
Age ≥ 18 years
ECOG 0 or 2 4 .Oligometastatic disease (1-5 radiotracer avid disease sites) on 18F- piflufolastat PET/CT within 30 days of trial recruitment
Known allergy/hypersensitivity to PSMA-targeted imaging agents
Other active malignancy, other than the known prostate cancer
Hoag Memorial Hospital Presbyterian
Lead sponsor
Washington University School of Medicine
Collaborator
Nuclidium
Collaborator